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CHLORPHENTERMINE ("Lucofen") is 1-(p-chl()rophenyl)-2-nmethyl-2-aminopropane
hydrochloride. It is a synthetic amphetamine derivatc clainmed to have none of
the excitatory effects of the parenit substanice. The chemical relationship to
amphetamine may be seenl by a comparisotn of their formulx:
Chlorphentermine C1< >CH.,-C(CH3)2 --- NH.,HC1.
Amphetamine <-->CH., - CH(CH3)- NH_.
Initial trials suggested that it wvas anl effective appetite suppressalnt b1th in
animals and man (Holmii et al., 1960; Munie et al., 1960; Erlendsson et al., 1960;
Nordlander, 1961). In this paper we report a double-blind cross-ovcr trial of
chlorphenterniine in anmbulant obese patients onl a restricted diet.
METHODS.
A double-blind cross-over technique was used. The procedure followed was
the same as that previously used in a similar trial (Hadden anld Lucev, 1961).
Patients were given a standard 1,100 calorie diet, containinig 100 gn. of
carbohydrate, or told to continue with their existing diet if this was of a lower
calorie value. They were divided into two groups according to a sequenice
obtained from a table of randonm numbers. Patients were instructed to take one
tablet three times daily before meals (either chlorphenitermine 25 mgm. or placebo).
After four weeks on one type each patient received the alternative tablets for
the second four-week period. They were reviewed by one of us after four and
eight weeks. No direct enquiries were made about the patients' subjective im-
pressions of the drug or possible side effects. Only spontaneous complaints were
noted. Neither the patients, doctors, dietitians, nor the nursing staff knew which
tablets contained the active preparatioin.
THE PATIENTS.
The criteria for admission to the trial were as previously reported, all patienlts
being more than 15 per cent. above their standard weight. Eighteen completed
the trial out of the thirty-two who were initially accepted. The remainder (44
per cent.) failed to attend on one or more occasions and therefore could not be
included. The two groups are compared in Table 1. There is no significant
difference between Group A and Group B as regards age, height, initial weight
or percentage overweight. The two groups are therefore statistically comparable.
181TABLE 1.
COMIPARISON OF THE Two GROUPS.
GROUP A
Number - -
Age (years)
Height (inches) -
Initial weight (in lbs
*Standard weight (in I
Overweight (percento
9
- - 35.7+22.4
(13-75)
- - 63+3.1
(59 -69)
- 196.4 + 30.8
(158 - 261)
lbs.) - 139.8+ 17.5
(104 - 154)
age) - 41.3 + 24.0
(17-47.9)
Obesity of over 10 years' duration 5
Previously in similar trial - 8
Males - - - - 1
... 9
32.1 + 9.8
(19-46)
... 63+3.8
(60- 72)
... 199.2+24.0
(169-241)
... 144+17
(132- 182)
... 39.9+ 14.6
(16.1 - 61.8)
... 6
... 6
... 2
... t=0.449
0.7>p>0.6
... t= 0.120
p>O.9
... t=0.052
p>O.9
... t=0.516
0.7>p>0.6
... t=0.150
0.9>p>0.8
Values in columns 1 and 2 are means, standard deviations, and ranges.
Column 3 applies the "t" test of significance to the difference of the means.
*Tables of the Lifc Extension Institutc of Ncw York.
Eight patients of Group A and six of Group B had taken part in a double-blind
trial of diethylpropion immediately preceding the present trial. Of these eight
Group A patients, five lost weight, two gained, and one remained unchanged.
Five of the six patients in Group B had lost weight and one had remained un-
changed. Five patients in Group A and six in Group B had a history of obesity
exceeding ten years' duration.
Two patients in each group had mild diabetes mellitus, being managed by
dietary carbohydrate restriction albne. Two patients had had myocardial infarction
in the past and another had angina of effort. Four of the fifteen women had
oligomenorrhcea. Two female patients had a troublesome degree of hirsutism
with a male type of body hair distribution, and two others were partners of
infertile marriages. On the other hand, the heaviest patient in the series, a
woman of 18 st. 9 lb., had a family of eleven.
REsULTS.
The results are recorded in Table 2. It will be seen that the niean weight
change for the two groups together while on chlorphentermine (- 4.8 lb.),
exceeds the mean weight change of the two groups while on placebo (- 0.08 lb.).
The difference between these two means is significant (0.02>P>0.01).
Chlorphentermine is therefore an effective aid to weight loss; the results are
significant in spite of the small numbers taking part in the trial. Taking each
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GROUP BTABLE 2.
RESULTS.
No. OF
PATIENTS MEAN WEIGHT CHANGES IN LBS.
First month Second month First and second
9 Placebo Chlorphentermine months combined
Group A ... +0.44 ... -2.83 ... -2.38
First month Second month First and second
9 Chlorphentemiinic Placebo months combined
Group B ... -6.77 ... -0.61 ... -7.38
group separately, the weight loss on chlorphenternmine exceeded the weight
change on placebo to an extent which is also statistically significant (P>0.001 in
each case). Thus, chlorphentermine is effective even when treatment is preceded
by a month on placebo therapy. The difference between the total weight change
of the two groups over the two-month period of the trial is not significant
(0.3>P>0.2).
The best individual result was achieved in a 19-year-old male who lost 15 lb.
in four weeks while on chlorphentermine. Only one out of the total series failed
to lose weight during the period on chlorphentermine. Eleven gained weight
while on the placebo. There was no correlation between loss of weight and age,
height, sex, initial weight or the percentage by which the standard weight was
exceeded. The patients placed little emphasis on the effects of the drug on their
appetite but six volunteered that they felt less hungry while taking chlorphen-
termine. Three of these were amongst those who had originally complained of
excessive appetite.
SIDE EFFECTFS.
Only spontaneous statements by the patients were recorded. There were no
complaints of insomnia. On the contrary, one patient felt more sleepy while on
chlorphentermine. There were no complaints of restlessness or irritability and
there was no evidence of the development of psychotic symptoms. There was
no instance of any tendency to addiction during the period on chlorphentermine
and no patient experienced withdrawal symptoms. Three patients complained of
individual symptoms of nausea, heartburn, and lack of energy respectively.
Neither the patients with ischxmic heart disease nor those with diabetes mellitus
showed any deterioration.
DIscussIoN.
To lose weight one nmust eat less food than the body requires for energy
expenditure. Dietary restriction alone is often adequate, but there remains a
residue of cases who for one reason or another fail to lose weight while on an
allegedly low calorie intake. It is these cases of "refractory obesity" (Seaton
et al., 1961) who present the main challenge. Initial enthusiasm in the use of
amphetamine as an appetite suppressant was lessened when it was found that a
183very high proportion of patients dleveloped unplcasant and cven dangerous sidc
effects. Inisomnia and irritability were common while many cases becamc addicted
and developed a clinical picture indistinguishable from paranoid schizophrenlia.
Connell (1958) found withdrawal symptoms in twelve out of forty-two cases of
amphetamine psychosis. He stressed the danger of psychotic effects when using
amphetamine derivatives for weight reduction. No significant side effects in
eighteen patients were found during one month's treatment with chlorphentermine
in the present trial.
These results show that chlorphentermine is an effective aid in the treatnmenit
of obesity when combined with moderate dietary restriction. The mean weight
loss for the eighteen patients over four weeks was 4.8 lb. The results might have
been better were it not for the fact that fourteen of our patients had taken part
in a similar trial of diethylpropion in the three months preceding the present
trial, as the four who were not in the previous trial showed a mean- weight loss
of 7.8 lb. Chlorphenterinine appears to be less effective when given after four
weeks placebo therapy than when given at the commencement 'of the trial;
although the difference is not statistically significant. A similar phenomenon in
an' earlier trial,-using diethylpropion, was more marked. This -is in-keeping' with
the findings of Seaton et al., using diethylpropion and is a frequent findinhg in
similar trials of appetite suppressant agents, irrespective of the drug used. .Our
results compare favourably with the early reports on chlorphentermline (Erlends-
son, V. and.F., 1960, mean -weight loss over four weeks 3.5.-lb.;- Mune et al.,
1960, mean. weight loss over four weeks 4.8 lb.; General Practitioner Clinical
Trial, 1961, mean loss over four weeks, 4.5 lb.).
The retail cost of one month's treatment with c-hlorphentermine is 9s.'8d.
SUMMIARY.
A 'double-blind cross-over trial 'using chlorphentermine in coIljunction with
dietary restriction is described. Chlorphentermine is shown to' be'an effective
aid in the treatment of obesity. All patients with one exception lost weight while
on the drug. There was no evidence of central nervous system stimulation and
no serious side effects developed'during a four-week period on chlorphentermine.
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